Capricor Therapeutics (CAPR)

Executive Summary

Capricor Therapeutics is a clinical-stage biotechnology company developing innovative cell and gene therapies for Duchenne muscular dystrophy (DMD) and other serious diseases. Its lead product candidate, CAP-1002 (deramiocel), is an allogeneic cardiosphere-derived cell therapy designed to slow disease progression by reducing inflammation and promoting muscle regeneration. In 2025, Capricor reported positive top-line results from the Phase 3 HOPE-3 trial, demonstrating statistically significant improvement in key functional endpoints in DMD patients. The company is now preparing for a Biologics License Application (BLA) submission to the FDA, with potential accelerated approval under the regenerative medicine advanced therapy (RMAT) designation. Capricor's platform also includes exosome-based therapies, adding long-term pipeline value. With a focused strategy and strong clinical data, Capricor is well-positioned to bring the first disease-modifying therapy for advanced DMD to market.

Upcoming Catalysts (preview)

• Q3 2026BLA Submission for CAP-100280% success
• Q4 2026FDA Priority Review Decision70% success
• TBDUpdate on Exosome Platform Preclinical Data50% success